Improving the Antitumor Effect of Chemotherapy with Ocoxin as a Novel Adjuvant Agent to Treat Prostate Cancer
dc.contributor.author | Hernández Unzueta, Iera | |
dc.contributor.author | Benedicto García, Aitor | |
dc.contributor.author | Tellería González, Uxue | |
dc.contributor.author | Sanz, Eduardo | |
dc.contributor.author | Márquez Clavijo, Joana ![]() | |
dc.date.accessioned | 2023-06-20T16:56:42Z | |
dc.date.available | 2023-06-20T16:56:42Z | |
dc.date.issued | 2023-05-29 | |
dc.identifier.citation | Nutrients 15(11) : (2023) // Article ID 2536 | es_ES |
dc.identifier.issn | 2072-6643 | |
dc.identifier.uri | http://hdl.handle.net/10810/61503 | |
dc.description.abstract | Prostate cancer is one of the most common cancers among men. Although many patients respond favorably to first-line treatments, castration—and chemotherapy—resistance arises after a few years, leading to metastasis. Thus, new approaches are being investigated using natural supplements to reinforce current therapies. Ocoxin is a plant-based mixture with antitumor properties that have been proved in several cancers. Here, we evaluated the cytotoxic capacity of this compound itself and combined with Docetaxel, Enzalutamide and Olaparib as an adjuvant agent. We observed that Ocoxin reduced tumor cell viability; slowed down cell cycles; altered the expression of genes involved in DNA replication, cell cycles and the p53 signaling pathway; and reduced migratory capacity after stimulation with cancer-associated fibroblasts (CAFs) and osteoblasts in vitro and reduced tumor volume in vivo. The combination of the nutritional supplement with chemotherapy showed a higher cytotoxic effect than chemotherapy alone and reverted chemoresistance conferred by CAFs and osteoblasts. Moreover, the adjuvant therapy also improved the outcome in vivo compared to the treatment with solo chemotherapy, where mice developed smaller tumors and less angiogenesis. Therefore, Ocoxin arises as a good candidate for further studies in combination with current treatments for prostate-cancer patients. | es_ES |
dc.description.sponsorship | This research was partly funded by Catalysis S.L. | es_ES |
dc.language.iso | eng | es_ES |
dc.publisher | MDPI | es_ES |
dc.rights | info:eu-repo/semantics/openAccess | es_ES |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | |
dc.subject | prostate cancer | es_ES |
dc.subject | cancer nutrition | es_ES |
dc.subject | adjuvant | es_ES |
dc.subject | chemotherapy | es_ES |
dc.subject | resistance | es_ES |
dc.subject | tumor microenvironment | es_ES |
dc.subject | fibroblast | es_ES |
dc.subject | osteoblast | es_ES |
dc.title | Improving the Antitumor Effect of Chemotherapy with Ocoxin as a Novel Adjuvant Agent to Treat Prostate Cancer | es_ES |
dc.type | info:eu-repo/semantics/article | es_ES |
dc.date.updated | 2023-06-09T13:01:19Z | |
dc.rights.holder | © 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/ 4.0/). | es_ES |
dc.relation.publisherversion | https://www.mdpi.com/2072-6643/15/11/2536 | es_ES |
dc.identifier.doi | 10.3390/nu15112536 | |
dc.departamentoes | Biología celular e histología | |
dc.departamentoeu | Zelulen biologia eta histologia |
Files in this item
This item appears in the following Collection(s)
Except where otherwise noted, this item's license is described as © 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/ 4.0/).